What Centauri Therapeutics does

Centauri Therapeutics Limited is a UK-based clinical-stage biotechnology company founded in 2015 and headquartered at Alderley Park, Cheshire. The company develops immunotherapeutic candidates built on its proprietary Alphamer® platform, a class of synthetic antibody recruiting molecules (ARMs) that redirect naturally existing anti-alphaGal antibodies in the human body to target pathogens or cancer cells. Each Alphamer is modular, comprising a targeting moiety that recognizes the disease target, a proprietary stable linker, and an immunological effector moiety that displays sugar epitopes to recruit the host's pre-existing polyclonal antibody repertoire, producing a dual mechanism of direct pathogen inhibition plus immune activation.

The company's lead clinical candidate is CTX-187, developed under the ABX-01 programme, which targets multidrug-resistant Gram-negative bacterial infections, with an initial indication focused on lung infections in vulnerable and immune-compromised patients. CTX-187 entered Phase I first-in-human trials in early 2026 and received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026, conferring eligibility for priority review and additional market exclusivity under the GAIN Act. Earlier pipeline work includes CTX-09, a bifunctional immunotherapy molecule for which pre-clinical proof-of-concept data was published in 2025. The underlying Alphamer platform is also patented for oncology applications, representing a latent pipeline branch.

Centauri operates as a pre-revenue company with a business model centered on out-licensing or co-development partnerships with major pharmaceutical companies for global commercialization following successful clinical development. The company has raised approximately £30 million in Series A funding (original £24M in January 2022, extended by £6M from the AMR Action Fund in February 2026) plus $12.3 million in cumulative non-dilutive support from CARB-X since 2019 and a £1 million grant from PACE in 2024. Core institutional investors include Boehringer Ingelheim Venture Fund, Evotec SE, Novo Holdings REPAIR Impact Fund, and the AMR Action Fund, all of which hold board representation.

Name

Centauri Therapeutics

Legal name

Centauri Therapeutics Limited

Website

https://centauritherapeutics.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Centauri Therapeutics is a UK-based clinical-stage biotech developing Alphamer® antibody-recruiting immunotherapies, with lead candidate CTX-187 in Phase I trials for multidrug-resistant Gram-negative bacterial infections, pursuing future out-licensing partnerships with major pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Antimicrobial Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Immunotherapy platform
• Antimicrobial resistance therapeutics
• Antibody recruiting molecules
• Clinical-stage biotechnology
• Infectious disease treatments

Headquarters

HQ city

Alderley Park

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pre-revenue / Pipeline Development: Centauri Therapeutics is a pre-revenue clinical-stage biotech company. The company is developing immunotherapeutic candidates (CTX-187 in ABX-01 programme) through clinical trials. Revenue generation is expected through out-licensing, co-development partnerships, or eventual product commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Centauri Therapeutics is a clinical-stage biotechnology company developing immunotherapeutic treatments through its proprietary Alphamer® platform technology. The platform uses synthetic Antibody Recruiting Molecules (ARMs) to redirect naturally existing polyclonal anti-alphaGal antibodies against pathogens or cancer cells, combining direct antibacterial activity with immune activation. The lead candidate CTX-187 targets multidrug-resistant Gram-negative bacterial infections and is currently in Phase I clinical trials, with planned out-licensing or co-development with major pharmaceutical companies for eventual commercialization.

Product overview

Centauri Therapeutics is an immunotherapy company with a proprietary Alphamer® platform technology applicable across infectious diseases and oncology. The company's current focus is on developing novel treatments for infectious diseases, particularly antimicrobial resistance. The core Alphamer® platform uses synthetic molecules to redirect naturally existing antibodies to treat life-threatening diseases. The lead clinical programme is ABX-01 with CTX-187 as the lead candidate targeting multidrug-resistant Gram-negative bacterial infections. Additional compounds including CTX-09 have demonstrated proof-of-concept activity. The platform also has potential applications in oncology with proof-of-concept data generated.

Differentiator

Problem solved

Functional benefit

Products and services

• Alphamer® Platform Proprietary immunotherapy technology platform that uses synthetic Antibody Recruiting Molecules (ARMs) to redirect pre-existing natural anti-alphaGal antibodies to treat life-threatening diseases. The platform comprises three modular components: targeting moiety, stable linker, and immunological effector moiety displaying sugar epitopes. Applicable across infectious diseases and oncology indications.
• ABX-01 Programme Clinical development programme focused on broad-spectrum antimicrobial candidates targeting antibiotic-resistant Gram-negative bacteria. Lead compound is CTX-187, currently in Phase I clinical trials. Supported by CARB-X with $12.3M total funding since 2019.
• CTX-187 Broad-spectrum antimicrobial immunotherapy candidate built on the Alphamer® platform, targeting multidrug-resistant Gram-negative bacteria. Combines immunotherapeutic effects with intrinsic antibacterial activity as a dual-mechanism therapy for Gram-negative bacterial infections including lung infections. Currently in Phase I clinical trials with FDA QIDP designation granted in March 2026.
• CTX-09 Novel bifunctional immunotherapy molecule based on Alphamer® platform demonstrating direct, broad-spectrum antibacterial activity in vitro and in vivo with enhanced immune activation through anti-alphaGal antibody recruitment. Represents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections.

Quantifiable outcome

• First pre-clinical proof-of-concept demonstrating endogenous antibody recruitment to address multi-drug resistant Gram-negative infections

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• BioVersys AG: Swiss clinical-stage AMR biotech developing small-molecule therapeutics targeting drug-resistant infections, also backed by AMR Action Fund and CARB-X. Most directly comparable peer given shared investor base, AMR focus, and clinical-stage status.
• Elion Therapeutics: AMR-focused biotech developing novel anti-infectives, with AMR Action Fund board representation. Comparable as a privately-held AMR developer with shared strategic backers.
• AUROBAC Therapeutics: AMR-focused biotech spun out of Evotec/GSK/University of Lyon consortium, with Antonio Felici (Centauri board member from Evotec) serving as board director. Highly comparable AMR pipeline and stage.
• Utility Therapeutics: AMR-focused biotech developing therapies for drug-resistant infections, backed by AMR Action Fund. Comparable size, stage, and AMR focus with shared lead investor.
• Phare Bio: AMR-focused biotech using AI/ML for antibiotic discovery targeting Gram-negative infections. Comparable target indication (MDR Gram-negative) and AMR strategic positioning.
• F2G Ltd: UK-based clinical-stage anti-infective biotech (antifungal) with similar size, stage, and European base. Comparable as a small-cap European anti-infective developer addressing resistant pathogens.

Emerging players

• VenatoRx Pharmaceuticals: CARB-X portfolio company developing novel antibiotics against MDR Gram-negative bacteria. Comparable target pathogen class and non-dilutive funding pathway.
• Adaptive Phage Therapeutics: Clinical-stage developer of phage-based therapies targeting MDR bacterial infections. Comparable AMR focus and clinical stage, but uses a different (phage) therapeutic modality.
• Iterum Therapeutics: Anti-infective company developing oral antibiotics for MDR Gram-negative infections. Comparable target indication but at a more advanced (commercial) stage with oral sulopenem.
• Melinta Therapeutics: Anti-infective company focused on serious bacterial infections including Gram-negative pathogens. Comparable AMR focus as a commercial-stage specialty anti-infective player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/centauri-therapeutics-limited

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Centauri Therapeutics